Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement

por Fernandes, Laura L., Zhou, Jiaxi, Kanapuru, Bindu, Horodniceanu, Erica, Gwise, Thomas, Kluetz, Paul G., Bhatnagar, Vishal
Publicado 2021

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials

por Kanapuru, Bindu, Fernandes, Laura L., Fashoyin-Aje, Lola A., Baines, Andrea C., Bhatnagar, Vishal, Ershler, Rachel, Gwise, Thomas, Kluetz, Paul, Pazdur, Richard, Pulte, Elizabeth, Shen, Yuan-Li, Gormley, Nicole
Publicado 2022

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data

por Maignan, Kathleen, Fashoyin-Aje, Lola A., Torres, Aracelis Z., Fernandes, Laura L., Gwise, Thomas, Baxi, Shrujal B., Roose, James P., Rivera, Donna R., Shen, Yuan Li, Kluetz, Paul G., Gormley, Nicole J.
Publicado 2022

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

por Suzman, Daniel L., Agrawal, Sundeep, Ning, Yang‐min, Maher, V. Ellen, Fernandes, Laura L., Karuri, Stella, Tang, Shenghui, Sridhara, Rajeshwari, Schroeder, Jason, Goldberg, Kirsten B., Ibrahim, Amna, McKee, Amy E., Pazdur, Richard, Beaver, Julia A.
Publicado 2018